Piper Sandler analyst David Amsellem lowered the firm’s price target on Biogen (BIIB) to $135 from $138 and keeps a Neutral rating on the ...

Biogen’s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated "sell" due to ...

Biogen (NASDAQ:BIIB – Free Report) had its target price lowered by Truist Financial from $220.00 to $210.00 in a research ...

Biogen (NASDAQ:BIIB – Free Report) had its price target trimmed by HC Wainwright from $300.00 to $241.00 in a report issued ...

TD Cowen analysts adjusted their outlook on Biogen (NASDAQ:BIIB) shares, reducing the price target to $200 from the previous $275, while sustaining a Buy rating on the stock. The revision reflects ...

Biogen (NASDAQ:BIIB) shares experienced a change in market expectations as Cantor Fitzgerald revised the company's price target. The new target has been set at $206.00, a decrease from the previous ...

Leqembi And Skyclarys Expected To Drive Biogen's Future Growth: Analysts Biogen's Q4 EPS and revenue topped estimates, but analysts cite Medicare changes and MS declines as headwinds. Leqembi and ...

BMO Capital analyst Evan Seigerman lowered the firm’s price target on Biogen (BIIB) to $139 from $156 and keeps a Market Perform rating on the ...

Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is ...